Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04012892 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions

COMBINATION_PRODUCT: CD19 CART

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]
[object Object]